Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Belimumab in Idiopathic Inflammatory Myositis (BIM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02347891
Recruitment Status : Active, not recruiting
First Posted : January 28, 2015
Last Update Posted : September 10, 2019
Information provided by (Responsible Party):
Galina Marder, MD, Northwell Health

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : December 2020
Estimated Study Completion Date : December 2020